NCT06108232View on ClinicalTrials.gov

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Follicular LymphomaTumor

Interventions

DRUG

Obinutuzumab

Given by IV (vein)

DRUG

CC-99282

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06108232 - Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | Biotech Hunter | Biotech Hunter